Methods Of Selectively Treating Asthma Using IL-13 Antagonists

a selective treatment and asthma technology, applied in antibody medical ingredients, cleaning equipments, peptides, etc., can solve the problems of significant unmet medical needs and major global health burden of asthma, and achieve the effects of minimizing the risk of il-13 antagonism, reducing the frequency of asthma exacerbations, and maximizing the benefi

Inactive Publication Date: 2019-03-21
NOVARTIS AG
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0008]There exists a need for identification of single nucleotide polymorphisms (SNP's) as being predictive of whether a patient having asthma will respond to a treatment with an IL-13 antagonist, as a pharmacogenomic biomarker approach to diagnosis and treatment of asthma. Provided herein are predictive methods and personalized therapies for patients having asthma that maximize the benefit and minimize the risk of IL-13 antagonism in these populations by identifying the patients likely to respond favorabl

Problems solved by technology

Asthma presents a major global health burden.
Despite existing therapies, there is still signi

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods Of Selectively Treating Asthma Using IL-13 Antagonists
  • Methods Of Selectively Treating Asthma Using IL-13 Antagonists
  • Methods Of Selectively Treating Asthma Using IL-13 Antagonists

Examples

Experimental program
Comparison scheme
Effect test

example 1

Identification of Il-13 Antagonists

[0169]For the purposes of the invention, IL-13 antagonists that compete with a specified anti-IL-13 antibody set forth herein, including antibody 01951 / G12 (SEQ ID NO:14 and 16) for binding to IL-13 can be identified by methods known in the art, and further as described in the following methodology.

All experiments are performed using a Biacore T200 instrument. Biacore T200 Control software and Biacore T200 Evaluation software are used for the control and analysis of experiments, respectively.

Part 1:

[0170]The anti-human IL-13 antibody ANTIBODY 01951 / G12 is immobilized to a CMS sensorchip surface using the amine coupling method. Briefly, the surface of the measuring flow cell is activated with EDC / NHS, followed by a 700 second addition of 50 μg / mL ANTIBODY 01951 / G12 in 10 mM sodium acetate pH 4.5. Based on previous experiments, these buffers and injection times are sufficient to allow saturation of the chip surface with ANTIBODY 01951 / G12, though exp...

example 2

Identification of the Antibody 01951 / G12 Epitope Residues:

Peptide Mapping:

[0173]The sequence of IL-13 was probed at the peptide level to identify the binding site with ANTIBODY 01951 / G12. Thirty four 15-mer peptides were synthesized in order to scan the entire sequence with 12 residue overlap starting from the N-terminus. The synthesis of the peptides, preparation of the peptide-array slides, incubation with antibodies and data analysis where done as described by Maksimov et al. (PLoS ONE 7(3): e34212).

[0174]The results are shown in Table 4. The binding signal intensity (light unit) observed is reported for each peptide, in column 1 against a control unrelated human antibody and in column 2 against ANTIBODY 01951 / G12. Signals above 10000 Light Units are considered as being significant. 2 overlapping peptides in the set of the 34 peptides produced a signal above that threshold, peptide 22 (TQRMLSGFCPHKVSA) (SEQ ID NO: 31) and peptide 23 (MLSGFCPHKVSAGQF) (SEQ ID NO: 32). The overlapp...

example 3

Pharmacogenetic Analysis of IL4-Rα SNPs and Discovery of AIR Markers 1-9:

[0176]ANTIBODY 01951 / G12 is a fully human IgG1 / κ monoclonal antibody. CQAX576A2207 was a Phase II clinical study to evaluate the effectiveness and safety of ANTIBODY 01951 / G12 in patients with moderate to severe persistent asthma following multiple doses, when added to existing asthma therapy.

[0177]To assess associations of several single nucleotide polymorphisms (SNPs) in the IL4-Rα gene and risk of asthma exacerbation in patients treated with ANTIBODY 01951 / G12, DNA was collected from patients enrolled in the CQAX576A2207 trial and nine SNPs in the IL4-Rα gene were genotyped in these samples. Statistical tests of association were performed to assess the evidence for association of SNPs in the IL4-Rα gene with risk of asthma exacerbation, as well as with other asthma clinical endpoints, in patients treated with ANTIBODY 01951 / G12.

[0178]In this manner, a pharmacogenetic analysis was undertaken, with the objecti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Massaaaaaaaaaa
Login to view more

Abstract

The disclosure is directed to novel predictive methods and personalized therapies for treating asthma. Specifically, this disclosure relates to methods of treating a patient having asthma by selectively administering an IL-13 antagonist, on the basis of that patient being genetically predisposed to have a favorable response to treatment with the IL-13 antagonist. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having asthma will respond to treatment with an IL-13 antagonist.

Description

SEQUENCE LISTING[0001]The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 19, 2015, is named PAT056217-WO-PCT_SL.txt and is 40,804 bytes in size.TECHNICAL FIELD[0002]The disclosure is directed to predictive methods, personalized therapies, transmittable forms of information and methods for treating patients having asthma.BACKGROUND OF THE DISCLOSURE[0003]Asthma presents a major global health burden. Despite existing therapies, there is still significant unmet medical need in asthma, with an estimated 300 million people affected worldwide. The World Health Organization estimates that 15 million disability-adjusted life years are lost annually due to asthma, representing 1% of the total global burden. Annual worldwide deaths have been estimated at 250,000. Uncontrolled asthma has a prevalence of greater than 6 million patients worldwide.[000...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A47L9/04A47L5/30A47L9/32A47L9/16
CPCA47L9/325A47L9/1683A47L5/30A47L9/0455A47L9/0444A47L9/0477C07K16/244A61K2039/545A61K2039/55C07K2317/34C07K2317/76C07K2317/94
Inventor ROTTE, MICHAELLEWITZKY, STEVENDAMASK, AMY
Owner NOVARTIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap